Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05689229

Acronym

colistin

Enrollment

128

Registered

2023-01-19

Start date

2021-08-03

Completion date

2021-12-12

Last updated

2023-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary Bacterial Infection in COVID-19 Patients

Brief summary

Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.

Interventions

DRUGColistin

COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Covid-19 patients with secondary gram-negative bacterial infections

Exclusion criteria

* Patients with resistant bacterial strains to polymyxins * patients less than 18 years

Design outcomes

Primary

Measure	Time frame
Microbial eradication	10 days
Mortality	30 days

Secondary

Measure	Time frame
Nephrotoxicity	10 days

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026